Pharma fail: Concordia pulls bond as M&A flounders
With pharma firms under intense scrutiny in the US, Concordia Healthcare Corp has dropped a planned $950m bond for its $3.5bn acquisition of Amdipharm Mercury, as the debt financing encountered some resistance from investors. Max Bower reports.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: